Drug profile · INN
igovomab
INDIMACIS 125
igovomab (INDIMACIS 125) is a mucin-16 binding agent.
EMA: withdrawn Various (V09) V09IB03
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — igovomab
- Class
- Various (V09)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
igovomab (INDIMACIS 125) is a mucin-16 binding agent.
Key facts
INN igovomab
Brand INDIMACIS 125
Mechanism Mucin-16 binding agent
Target Mucin-16
Therapeutic class Various (V09)
ATC code V09IB03
Mechanism of action
Mucin-16 binding agent
Primary target: Mucin-16
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is igovomab?
igovomab (INDIMACIS 125) is a mucin-16 binding agent.
What is the brand name for igovomab?
INDIMACIS 125 is a marketed brand name for igovomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.